개방각 녹내장 치료제 시장 : 제품, 약물군, 유통 채널, 최종사용자별 - 세계 예측(2025-2030년)

The Open-Angle Glaucoma Therapeutics Market was valued at USD 8.64 billion in 2023, expected to reach USD 9.35 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 15.53 billion by 2030.

Open-angle glaucoma therapeutics refer to the treatments aimed at lowering intraocular pressure to prevent damage to the optic nerve, which can lead to irreversible vision loss. This market encompasses a variety of medical interventions, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, and combination drugs. The necessity of these treatments stems from the disease's prevalence as the most common form of glaucoma, particularly affecting older populations where early diagnosis and effective management are crucial to maintaining quality of life. Application settings include hospitals, ophthalmology clinics, and research institutions, where these therapeutics are integral to both ongoing patient care and novel treatment development. Increased healthcare awareness and a growing aging demographic persist as key growth drivers, while advancements in drug formulations enhance efficacy and patient compliance. Emerging opportunities lie in the development of sustained-release drug delivery systems and personalized medicine approaches that promise optimized, individualized treatment regimens. Collaborative partnerships between pharmaceutical companies and research institutes are advised to accelerate innovation.

Yet, the market encounters limitations such as stringent regulatory approvals, high costs of new drug development, and competition from alternative therapies such as surgery or laser treatments. Additionally, patient adherence remains a challenge due to the asymptomatic nature of the disease and side effects of long-term drug use. Efforts to address these include creating cost-effective, patient-friendly formulations and investing in patient education programs to increase compliance. The market's innovative edge lies in targeting neuroprotective strategies that could protect the optic nerve beyond just lowering intraocular pressure, as well as exploring gene therapy options. As the landscape evolves, staying attuned to regulatory changes and technology integration will be pivotal for maintaining a competitive advantage in the open-angle glaucoma therapeutics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Open-Angle Glaucoma Therapeutics Market

The Open-Angle Glaucoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of glaucoma globally
  • Increasing demand for combustion drugs
  • Improving diagnostic tools to detect glaucoma
• Market Restraints
  • Rising drug recalls for glaucoma treatments
• Market Opportunities
  • Growing approvals for open-angle glaucoma therapies
  • Rising introduction of advanced open-angle glaucoma therapies
• Market Challenges
  • Lack of experienced ophthalmologists

Porter's Five Forces: A Strategic Tool for Navigating the Open-Angle Glaucoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Open-Angle Glaucoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Open-Angle Glaucoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Open-Angle Glaucoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Open-Angle Glaucoma Therapeutics Market

A detailed market share analysis in the Open-Angle Glaucoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Open-Angle Glaucoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Open-Angle Glaucoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Open-Angle Glaucoma Therapeutics Market

A strategic analysis of the Open-Angle Glaucoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Open-Angle Glaucoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Bausch Health Co. Inc., D.Western Therapeutics Institute Inc, EyePoint Pharmaceuticals, Inc., Fera Pharmaceuticals, Hikma Pharmaceuticals PLC, Iridex Corporation, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Open-Angle Glaucoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Non-PGAs and PGAs.
• Based on Drug Class, market is studied across Bimatoprost, Latanoprost, Travoprost, and Unoprostone.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of glaucoma globally
    • 5.1.1.2. Increasing demand for combustion drugs
    • 5.1.1.3. Improving diagnostic tools to detect glaucoma
  • 5.1.2. Restraints
    • 5.1.2.1. Rising drug recalls for glaucoma treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing approvals for open-angle glaucoma therapies
    • 5.1.3.2. Rising introduction of advanced open-angle glaucoma therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of experienced ophthalmologists
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Open-Angle Glaucoma Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Non-PGAs
• 6.3. PGAs

7. Open-Angle Glaucoma Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Bimatoprost
• 7.3. Latanoprost
• 7.4. Travoprost
• 7.5. Unoprostone

8. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retail Pharmacy

9. Open-Angle Glaucoma Therapeutics Market, by End Users

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Ophthalmic Clinics

10. Americas Open-Angle Glaucoma Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Open-Angle Glaucoma Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcon Inc.
• 3. Bausch Health Co. Inc.
• 4. D.Western Therapeutics Institute Inc
• 5. EyePoint Pharmaceuticals, Inc.
• 6. Fera Pharmaceuticals
• 7. Hikma Pharmaceuticals PLC
• 8. Iridex Corporation
• 9. Laboratories Sophia
• 10. Merck and Co. Inc.
• 11. Nicox SA
• 12. Novartis AG
• 13. Pfizer Inc.
• 14. Sun Pharmaceutical Industries Ltd.
• 15. Teva Pharmaceutical Industries Ltd.